Clinical trial · Observational
Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Endometrial cancer (EC) is one of the most common gynecological neoplasms, being the second in incidence and third in mortality in Mexico. Recent studies show that EC molecular classification (Cancer Genome Atlas Research Network, 2013) serves to establish a more accurate prognosis in these patients and regulate therapeutic behavior in a personalized manner. However, there are no studies on EC molecular classification in Mexican women or its impact on prognosis and the possible modification of targeted treatment. The investigators will determine the molecular classification in EC by next-generation sequencing (NGS) to detect TP53 and POLE somatic mutations, and immunohistochemical detection of microsatellite instability (MSH2, MLH1, PMS1, PMS2, MSH6, and MSH3) in a cohort of patients with endometrioid-type EC, endometrioid subtype, attended at the Instituto Nacional de Cancerología - Mexico (INCan) and determine its impact on clinical prognosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Descriptive and analytical | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with EC endometroid
- description
- Patients with EC endometroid subtype and peripheral blood, treated during 2015-2019 at the INCan.
- interventionNames
- Genetic: Descriptive and analytical
Primary outcomes (4)
- measure
- sequence the exome
- timeFrame
- 2024-2025
- description
- Molecular classification of endometroid-type endometrial cancer in Mexican participants based on POLE and TP53 mutations as well as makers of microsatellite instability (MSH2, MLH1, PMS1, PMS2, MSH6, and MSH3).
- measure
- Determine POLE mutations
- timeFrame
- 2024-2025
- description
- Determine POLE mutations by massive next-generation sequencing of a discovery cohort in patients with endometroid-type EC.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Criteria: Inclusion Criteria: * Clinical diagnosis of endometrioid-type endometrial cancer with samples available * That the patients have undergone surgery at INCan. Exclusion Criteria: * Samples with CEE of non-endometroid type. * Samples from patients with double primary neoplasm, including carcinoma ductal in situ, squamous cell skin cancers, and cervical carcinoma in situ * History of malignancy \< 5 years prior with no evidence of disease (i.e., remission).
References
Publications (0)
Data not yet available